The new tool, named GI SereniT, now available via the company’s international clinical programme Floré Clinical, provides clinically relevant insight into gut dysbiosis, microbiome diversity, pathogenic bacteria, IBS, IBD and more.
Since its founding in 2016, Sun Genomics has been using a patented methodology based on the extraction of DNA from stool samples alongside lifestyle surveys, to provide customers with fully personalised probiotics on a monthly subscription basis.
The newly launched tests are now available via the California-based firm's partnering health clinics across the US and UK, allowing health professionals utilise data which identifies and detects bacteria, yeast and parasites of over 100,000 genomes and 25,000 species-level organisms.
The insights from the new test go beyond the original microbiome analysis tool utilised by the firm, which gives consumers a general gut health score.
A spokesperson for the firm explains: "It looks for and analyzes the relative abundances of bacteria, yeast and parasites of over 100,000 genus and 25,000 species-level organisms on every test. Alongside Whole Genome Sequencing (WGS), it incorporates qPCR methodology to detect and identify >90% of causative bacterial, viral and parasitic agents of gastroenteritis.
"From there, a provider could recommend the Floré customized program to address and amend any issues found in the GI SereniT assessment – and bring the microbiome back to symbiosis. After identifying imbalances in the gut that may be causing common G.I. issues, the personalized synbiotics are hand-formulated and cold shipped directly to the patient’s door."
The clinical tests will provide patients with insights into what their microbiome says about their immunity, joint health, longevity, and dysbiosis index. It will also provide risk predictions for chronic conditions such as inflammation, auto-immune disease, neurodegenerative disorders, Crohn’s disease, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).
Practitioners can then refer patients to three-month, six-month or 12-month Floré customised probiotic/prebiotic programme based on the results.
Last year, Floré launched three new clinical tests for inflammation, gastrointestinal pathogens and heavy metal to help a broader population identify and address a variety of gut health issues.
In January this year, the firm partnered with DSM Venturing in an aim to expand on the science and the commercial availability of precision probiotics around the globe.
The companies matched during the recent MassChallenge Switzerland Sustainable Food Solutions Challenge after realising their shared commitment to the science behind probiotics and their role in improving the health and wellness of the global population.
Sunny Jain, chief executive officer and founder of Floré, said at the time of the partnership: “We are proud to partner with DSM to expand our research and product efforts and help bring precision nutrition to all,” said . “By utilizing DSM’s resources and expertise in the biotech space, we are grateful to receive the support required to grow our customer base and maintain our position as a leader in precision probiotics and nutrition.”